drugset / Trial / NCT01968902

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

NCT01968902

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if Xeomin® will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.

Timeline

Start
2013-11
Primary completion
2016-01-27
Completion
2016-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 200 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 400 iu Intramuscular

Indications